FGF21 and diabetes mellitus: Indeed, long-term administration of two other FGF-21-based bioengineered drugs, BMS-986036 and AKR-001, significantly reduced blood glucose levels in patients with diabetes (Charles et al., 2019; Harrison et al., 2021).